116 related articles for article (PubMed ID: 20081266)
1. [Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study].
Ługowska I; Woźniak W; Ambroszkiewicz J; Gajewska J; Szamotulska K
Med Wieku Rozwoj; 2009; 13(3):201-8. PubMed ID: 20081266
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
4. The levels of bone alkaline phosphatase (BALP) and soluble epidermal growth factor receptor-2 (ECD/HER-2) in pediatric patients with osteosarcoma during clinical treatment.
Rychłowska-Pruszyńska M; Gajewska J; Ambroszkiewicz J; Karwacki M; Szamotulska K
Dev Period Med; 2018; 22(1):58-64. PubMed ID: 29641422
[TBL] [Abstract][Full Text] [Related]
5. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
Ardavanis A; Kountourakis P; Kyriakou F; Malliou S; Mantzaris I; Garoufali A; Yiotis I; Scorilas A; Baziotis N; Rigatos G
Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
[TBL] [Abstract][Full Text] [Related]
7. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
[TBL] [Abstract][Full Text] [Related]
8. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report].
Markiewicz K; Zeman K; Kozar A; Gołebiowska-Wawrzyniak M
Med Wieku Rozwoj; 2011; 15(1):25-31. PubMed ID: 21786509
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Boye K; Del Prever AB; Eriksson M; Saeter G; Tienghi A; Lindholm P; Fagioli F; Skjeldal S; Ferrari S; Hall KS
Pediatr Blood Cancer; 2014 May; 61(5):840-5. PubMed ID: 24254749
[TBL] [Abstract][Full Text] [Related]
12. Soluble p185(HER-2) in patients with malignant bone tumours.
Holzer G; Pfandlsteiner T; Koschat M; Noske H; Trieb K; Kotz R
Pediatr Blood Cancer; 2005 Feb; 44(2):163-6. PubMed ID: 15468309
[TBL] [Abstract][Full Text] [Related]
13. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
14. [Biochemical bone resorption markers in children with osteosarcoma].
Ambroszkiewicz J; Gajewska J; Laskowska-Klita T; Woźniak W
Med Wieku Rozwoj; 2004; 8(2 Pt 1):225-33. PubMed ID: 15738598
[TBL] [Abstract][Full Text] [Related]
15. Plasma proteome predicts chemotherapy response in osteosarcoma patients.
Li Y; Dang TA; Shen J; Hicks J; Chintagumpala M; Lau CC; Man TK
Oncol Rep; 2011 Feb; 25(2):303-14. PubMed ID: 21165584
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
[TBL] [Abstract][Full Text] [Related]
19. The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma.
Kaya M; Wada T; Nagoya S; Sasaki M; Matsumura T; Yamashita T
J Bone Joint Surg Br; 2009 Jun; 91(6):784-8. PubMed ID: 19483233
[TBL] [Abstract][Full Text] [Related]
20. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
